Boehringer Ingelheim announced results on October 1, 2026, from SYNCHRONIZE-2, a Phase 3 trial of survodutide, its glucagon/GLP-1 receptor dual agonist, in adults living with both obesity (or overweight) and type 2 diabetes. The trial reported mean weight loss of up to 13.1% at the higher dose, alongside clinically meaningful improvements in blood sugar control — a combination that's been harder to demonstrate in this specific, harder-to-treat population than in obesity trials without diabetes.
What the Trial Found
SYNCHRONIZE-2 was a 76-week, double-blind, placebo-controlled study enrolling 755 adults with obesity or overweight and type 2 diabetes, testing weekly injections of survodutide at 3.6 mg or 6.0 mg doses against placebo. Participants on survodutide lost up to 13.1% of their body weight on average, compared with 3.1% in the placebo group, a difference Boehringer Ingelheim reported as statistically significant (p < 0.0001). Nearly 80% of survodutide-treated participants achieved at least 5% weight reduction, versus about a third of those on placebo. Waist circumference dropped by 11.1 cm on survodutide, compared with 3.5 cm on placebo.
On the glycemic side, the company reported an HbA1c reduction of up to 1.21 percentage points from a baseline around 7.4%, compared with essentially no change (0.03 points) in the placebo group. Nearly 30% of participants on survodutide saw their blood sugar return to the normal range (normoglycemia), compared with 4% on placebo — a result the company highlighted as evidence the drug's metabolic effects go beyond weight loss alone.
Tolerability
As with other drugs in this class, gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — were the most common adverse events. Discontinuations specifically due to GI side effects were notably higher on survodutide than placebo (reported around 18% versus roughly 1%), a reminder that even with strong average results, a meaningful share of patients in a trial this size don't tolerate the drug at these doses well enough to stay on it for the full 76 weeks.
What Survodutide Is
Survodutide is a dual agonist that activates both the glucagon receptor and the GLP-1 receptor, a mechanism distinct from single-target drugs like semaglutide and intended to add glucagon's effects on energy expenditure and liver fat to GLP-1's effects on appetite and blood sugar. It's being co-developed with Zealand Pharma, which licensed the molecule to Boehringer Ingelheim and receives royalties on sales if it's eventually approved. Survodutide is not FDA-approved for any use; it remains investigational and is being studied across a broader program that includes a dedicated type 2 diabetes trial (SYNCHRONIZE-T2D) and a trial in metabolic dysfunction-associated steatohepatitis (MASH), called LIVERAGE MASH.
What Comes Next
Boehringer Ingelheim said cardiovascular outcomes data from the broader SYNCHRONIZE program are expected later in 2026, which will matter for how survodutide is eventually positioned relative to approved GLP-1 drugs that already have heart-health data on their labels. A regulatory filing has not yet been announced, and until the FDA reviews a complete application, survodutide's eventual approved uses, dosing, and label warnings remain undetermined.
For people managing obesity and type 2 diabetes together, these are promising early signals from a well-designed trial, not a treatment currently available outside of clinical trial enrollment. Anyone interested in how dual and multi-agonist peptides compare to currently available options should talk with an endocrinologist or their prescribing physician about what's actually available today versus what's still in development.